-Non-Alcoholic Beer Market to hit $40 Billion by 2032, Says Global Market Insights inc.-The Access Group Completes Acquisition of COINS Fueling Global ERP Growth-Data Center Cooling Market to hit $45 Bn by 2032, Predicts Global Market Insights Inc.-New Cirium Airline Finance Rankings Show an Industry Net Loss of Nearly $220 Billion Since the Pandemic Began-Benchmark International Facilitated the Transaction of Metro-Tech Electrical Contractors, Inc. to Michael Bowman-OLED Will Advance from Smartphone to IT Products as Related Large-Generation Fabs Are Being Planned, but Evaporation Equipment Poses Challenges, Says TrendForce-Gensource Announces $6,000,000 Non-Brokered Private Placement-The Pershing Square Funds Announce the Final Results of Their Tender Offer for Common Shares of The Howard Hughes Corporation-Liminatus Pharma LLC and Iris Acquisition Corp to combine to incorporate and accelerate much-needed cancer treatments-Edge Total Intelligence Inc. Reports Third Quarter 2022 Results and Provides Operational Outlook-UpperEdge Announces First-of-its-Kind Integrated Sourcing Strategy for SAP S/4HANA Transformations-Tachus Fiber Internet Lights 25,000th Residential Customer-Seanergy Maritime Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2022 and Declares Cash Dividend of $0.025 Per Share-Victoria’s Secret & Co. Reports Third Quarter 2022 Results-La-Z-Boy Reports Record Fiscal 2023 Second-Quarter Results; Increases Dividend By 10%-ATA Creativity Global Reports 2022 Third Quarter Financial Results-nCino Reports Third Quarter Fiscal Year 2023 Financial Results-Credo Technology Group Holding Ltd Reports Second Quarter of Fiscal Year 2023 Financial Results-Genasys Inc. Reports Fiscal Fourth Quarter and Full Year 2022 Financial Results-Five Below, Inc. Announces Third Quarter Fiscal 2022 Financial Results

Future Markets Research Releases Commentary on NurExone Biologic Inc, An Emerging Leader in The Exosomal Treatment of Spinal Cord Injury

LONDON–()–The Future Markets Research Tank (FMRT) is proud to release market commentary on NurExone Biologic (TSXV: NRX) (FSE: J90), an innovative biotechnology company poised to disrupt the spinal cord injury treatment industry and the exosome research landscape. To read the full report click here, or follow the link: https://bit.ly/3UW9TzC

Key Insights:

  • Each year, hundreds of thousands of people suffer from spinal cord injury. In addition, poor medical care and the lack of availability of effective treatments contribute to an increase in SCI patient mortality and disability.
  • With rising numbers of workplace accidents, road accidents, and other medical conditions, the global SCI therapeutics market is anticipated to grow at a Compound annual growth rate (CAGR) of 17.84% to reach US$9.61 billion by 2028. There is a pressing need to create novel therapeutics to treat SCI due to the exorbitant cost of spinal surgery procedures and related healthcare costs.
  • In parallel, the global exosome market is estimated to grow at a CAGR of more than 34% between 2022 and 2030, reaching a market value of around USD 2,273 million by 20303
  • NurExone Biologic is an exciting company that sits at the forefront of these two fast growing arenas. With their unique ExoTherapies, NurExone is making significant advancements towards becoming a market leader in exosome-based treatment for acute spinal cord injuries. As the company grows, it has announced numerous strategic initiatives, such as plans to expand its intellectual property portfolio and partnerships for advanced research.
  • Moreover, positive preliminary findings prove the company’s potential and distinguish itself as an emerging exosome leader with an intriguing biotechnology portfolio and offering. As the company continues innovating and achieving meaningful milestones, they are well positioned to become a leading biotech company and central player in both the exosome and the spinal cord treatment arenas.

To read the full report click here, or follow the link: https://bit.ly/3UW9TzC

Leave a Comment